BUZZ-iBio股价上涨,因肥胖症药物获准在澳进行首次人体试验

路透中文
Apr 08
BUZZ-iBio股价上涨,因肥胖症药物获准在澳进行首次人体试验

4月8日 - ** 生物技术公司iBio IBIO.O股价盘前上涨7%至2.25美元

** 该公司称澳大利亚监管机构已批准对其实验性肥胖症药物IBIO-600进行首次人体研究

** 该药物针对肥胖症,目的是在减肥的同时保持肌肉 - IBIO

** 称 IBIO-600 可与 GLP-1 减肥药同时使用,后者会导致肌肉流失

** 补充说早期研究将测试安全性以及该药物在超重和肥胖成年人中的表现

** 称动物实验显示瘦肌肉增加,脂肪减少;药物一年只需服用几次

** 截至上次收盘,IBIO 年累计涨幅约为 9%

(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10